The Exchange had sought clarification from JHS Svendgaard Laboratories Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results not signed by authorized signatory/ies. The response of the Company is enclosed.
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
NSE had asked JHS Svendgaard Laboratories to explain why the financial results for the quarter ended December 31, 2025 were not signed by an authorized signatory. The company responded that the results were approved by the Board on February 10, 2026, and were signed by Mr. Vinay Mittal, a Director, who was duly authorized to do so. To support this, the company has enclosed a certified true copy of the Board Resolution, which authorized the Managing Director Mr. Nikhil Nanda or, in his absence, any other Director to sign the results. The company has confirmed that it has complied with Regulation 33(2)(b) of SEBI's Listing Regulations. It has requested the exchange to treat the matter as closed.
This is a routine procedural compliance clarification with no impact on the company's financials, operations, or shareholders. It addresses a paperwork-related query from the exchange and does not signal any business or governance concern.